Detalhe da pesquisa
1.
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.
Blood
; 138(18): 1705-1720, 2021 11 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34077955
2.
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Br J Cancer
; 125(12): 1666-1676, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34663950
3.
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
J Clin Invest
; 134(2)2024 Jan 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37934611
4.
Epitope Lability of Phosphorylated Biomarkers of the DNA Damage Response Pathway Results in Increased Vulnerability to Effects of Delayed or Incomplete Formalin Fixation.
J Histochem Cytochem
; 71(5): 237-257, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37119278
5.
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.
Mol Cancer Ther
; 20(2): 238-249, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33273059
6.
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Nat Commun
; 10(1): 5065, 2019 11 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31699977